Pfizer CEO: How AI Will Reshape the Future of Medicine | Podcast | In Good Company
Pfizer CEO Albert Bourla discusses leveraging COVID-19 vaccine success to build organizational resilience, executing $80+ billion in strategic acquisitions targeting antibody-drug conjugates and obesity treatments, and restructuring R&D to double clinical success rates, while predicting AI will fundamentally reshape medicine within five years.